Home
Login
Sign Up
 
 

Message

Wed, June, 16th 2021
Message Link »
View »
Loring Kaveney Healthcare
BC:
The intravenous drug aducanumab, marketed under the name Aduhelm, will comprise more than 1% of all national health spending by the mid-2020s. It will grow non-retail drug spending—those administered in hospitals or clinics—by at least 25%. Read more... https://www.modernhealthcare.com/finance/us-drug-spending-spike-least-8-mid-2020s-new-alzheimers-drug?utm_medium=social&utm_source=twitter&utm_term=modrnhealthcr&utm_content=fa9839fd-b0fd-4868-a04d-96b308fc3794 Show less...
Delivered Read

Online